Metabolic enzyme gene variants predispose children receiving a busulfan/cyclophosphamide-based myeloablative conditioning to veno-occlusive disease

被引：0
|
作者：
Huezo-Diaz, P. V. [1 ]
Uppungunduri, C. R. S. [1 ]
Tyagi, A. K. [1 ]
Rezgui, M. A. [2 ]
Bernard, F. [1 ]
Chalandon, Y. [3 ]
Duval, M. [2 ]
Bittencourt, H. [2 ]
Krajinovic, M. [2 ]
Ansari, M. [1 ]
机构：
[1] Univ Hosp Geneva, Fac Med, Geneva, Switzerland
[2] CHU St Justine Res Ctr, Charles Bruneau Canc Ctr, Montreal, PQ, Canada
[3] Univ Hosp Geneva, Geneva, Switzerland
来源：
BONE MARROW TRANSPLANTATION | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S220 / S221
页数：2
相关论文
共 49 条
  • [31] Association Between Busulfan First-Dose Pharmacokinetics and Outcome in Children Receiving Myeloablative Busulfan-Based Conditioning Before Unrelated Umbilical Cord Blood Transplantation for Malignancies
    Bittencourt, Henrique
    Rezgui, Mohamed Aziz
    Meziani, Samira
    Vachon, Marie-France
    Desjean, Catherine
    Duval, Michel
    Theoret, Yves
    Krajinovic, Maja
    Ansari, Marc
    BLOOD, 2012, 120 (21)
  • [32] Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Patients Receiving Inotuzumab Ozogamicin Followed By Total Body Irradiation-Based Conditioning for Stem Cell Transplantation: A Risk Mitigation Strategy
    Alahmadi, Ahmed
    Nasiri, Abdulrahman
    Samarkandi, Sarah
    Alothaimeen, Haya
    Nassar, Marwa
    Alahmari, Ali
    Alotaibi, Ahmad S.
    Alfayez, Mansour
    Alkhaldi, Hanan
    Saad, Ayman
    Ahmed, Syed Osman
    Hanbali, Amr
    BLOOD, 2024, 144 : 7306 - 7307
  • [33] Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning
    Li, Guifang
    Sun, Zimin
    Geng, Liangquan
    Wan, Xiang
    Zhu, Xiaoyu
    Tang, Baolin
    Tong, Juan
    Yao, Wen
    Song, Kaidi
    Qiang, Ping
    Zhang, Lei
    Zhang, Xuhan
    Zhang, Shiyang
    Liu, Huilan
    PEDIATRIC TRANSPLANTATION, 2022, 26 (02)
  • [34] Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia
    Hong, Kyung Taek
    Park, Hyun Jin
    Kim, Bo Kyung
    An, Hong Yul
    Choi, Jung Yoon
    Kang, Hyoung Jin
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (04): : 195.e1 - 195.e7
  • [35] Defibrotide prophylaxis of Veno-Occlusive disease in children with High-Risk Neuroblastoma treated with Busulfan-Melphalan High-Dose Chemotherapy and Autologous Stem Cell Transplantation
    Pasqualini, C.
    Cros, G.
    Dufour, C.
    Abbou, S.
    Dourthe, M. -E.
    Rigaud, C.
    Valteau-Couanet, D.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S260 - S260
  • [36] Intravenous (IV) vs oral busulfan (BU) as part of a BU/CY (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): Decreased incidence of hepatic veno-occlusive disease (VOD).
    Kashyap, A
    Wingard, J
    Cagnoni, P
    Tarantolo, S
    Fernandez, H
    Hu, W
    Gilfillan, K
    Faccuseh, M
    Niland, J
    Vaughan, W
    Jones, R
    Blume, K
    Champlin, R
    Forman, SJ
    Andersson, BS
    BLOOD, 1999, 94 (10) : 321B - 321B
  • [37] Busulfan/sulfolane metabolic ratio on day three of conditioning may predict the event-free survival in children receiving busulfan based conditioning prior to allogeneic hematopoietic stem-cell transplantation
    Uppugunduri, Chakradhara Rao S.
    Rezgui, Aziz
    Curtis, Patricia Huezo-Diaz
    Nava, Tiago
    Mlakar, Simona
    Theoret, Yves
    Bittencourt, Henrique
    Krajinovic, Maja
    Ansari, Marc
    BONE MARROW TRANSPLANTATION, 2019, 54 : 212 - 212
  • [38] Hepatic veno-occlusive disease (VOD) after allogeneic hematopoietic cell transplantation (HCT) in adults conditioned with busulfan (Bu) and cyclophosphamide (Cy) at a single center: A retrospective comparison of oral vs. intravenous Bu.
    Lee, JH
    Lee, JH
    Choi, SJ
    Kim, SE
    Seol, M
    Lee, YS
    Park, CJ
    Chi, HS
    Lee, JS
    Lee, KH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 594S - 594S
  • [39] Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen
    Popat, Uday
    Saliba, Rima M.
    Mehta, Rohtesh S.
    Olson, Amanda L.
    Chen, Julianne
    Ganesh, Christina
    Rondon, Gabriela
    Woodworth, Glenda
    McMullin, Becky
    Alousi, Amin M.
    Anderlini, Paolo
    Alatrash, Gheath
    Bashir, Qaiser
    Ciurea, Stefan O.
    Hosing, Chitra
    Im, Jin S.
    Kebriaei, Partow
    Khouri, Issa F.
    Marin, David
    Nieto, Yago
    Oran, Betul
    Saini, Neeraj
    Srour, Samer
    Rezvani, Katayoun
    Qazilbash, Muzaffar H.
    Molldrem, Jeffrey J.
    Shpall, Elizabeth J.
    Andersson, Borje S.
    Champlin, Richard E.
    BLOOD, 2019, 134
  • [40] Risk of engraftment failure and veno-occlusive disease in children who underwent allogeneic haematopoietic stem cell transplantation conditioned with a regimen containing oral busulfan compared to total body-irradiation
    Kawano, Y.
    Tabuchi, K.
    Kato, S.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S86 - S86
12345